On September 16, PHARMARON rose 3.26% in regular trading, trading at HK$29.58/share, with turnover of HK$18.94 million. The rally was driven by continued strength in the CRO/CDMO sector and a series of bullish catalysts surrounding the company.

On the sector front, WuXi AppTec's interim results significantly beat market expectations with an upward revision to full-year guidance, reinforcing the high-growth momentum across the CRO/CDMO industry. PHARMARON itself reported H1 revenue of RMB 7.595 billion, up 17.9% year-over-year, with CDMO revenue surging 32.8%. Management subsequently raised its full-year revenue growth guidance from 12%-18% to 15%-20%, citing strong customer demand and robust order trends through July and August.

On the institutional front, Daiwa, Bank of America, and Morgan Stanley raised their target prices to HK$38.5, HK$38.4, and HK$35.6 respectively, all maintaining buy or overweight ratings. Meanwhile, JPMorgan increased its long position to 11.43%, Morgan Stanley to 6.69%, and Citigroup to 5.54% in PHARMARON's H shares, signaling broad institutional conviction in the company's growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)